Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil

Merck & Co. reported stronger-than-expected third-quarter results, with revenue reaching $17.28 billion and adjusted EPS at $2.58, both surpassing analyst estimates, primarily driven by a 10% surge in Keytruda sales to $8.1 billion. Despite the beat, shares fell 3% premarket after the company narrowed its full-year revenue guidance to $64.5 billion-$65.0 billion, offsetting a slight increase in its EPS outlook. Investors are focused on Merck's significant reliance on Keytruda, which constitutes 47% of total sales and faces biosimilar competition later this decade, alongside broader industry pressures and the company's pipeline diversification efforts.

Analysis

Merck & Co. (MRK.N) reported a robust third quarter, with revenue reaching $17.28 billion and adjusted EPS at $2.58, both surpassing analyst estimates of $16.96 billion and $2.35 respectively. This performance was primarily driven by a 10% increase in blockbuster cancer drug Keytruda sales to $8.1 billion, aligning with analyst expectations. Despite beating top and bottom-line estimates, MRK shares experienced a 3% premarket decline.

The premarket share drop appears linked to Merck's decision to narrow its full-year revenue guidance to $64.5 billion-$65.0 billion, a slight reduction from the prior $64.3 billion-$65.3 billion range, despite a marginal increase in full-year EPS guidance to $8.93-$8.98. While Keytruda sales were strong, the human papillomavirus vaccine Gardasil saw sales fall to $1.75 billion, attributed to a halt in new shipments to China and reduced consumer spending impacting inventory.

A significant concern for investors remains Merck's high dependence on Keytruda, which constitutes over 47% of total sales and faces biosimilar competition later this decade. The company is actively pursuing pipeline diversification to mitigate this risk, alongside navigating broader industry headwinds such as potential U.S. drug pricing reforms. The cautious tone and negative per-ticker sentiment (-0.2) reflect these long-term strategic challenges.

Key Decisions for Investors

• Monitor Merck's pipeline diversification progress closely, as Keytruda's significant revenue contribution (47%) faces biosimilar competition later this decade.
• Assess the implications of the narrowed full-year revenue guidance, which overshadowed strong Q3 beats, indicating potential top-line growth challenges beyond Keytruda.
• Evaluate the ongoing impact of broader industry headwinds, including potential U.S. drug pricing reforms and regional demand shifts like those affecting Gardasil in China, on future earnings stability.